Gold Standard Diagnostics’ Next-Generation Lyme Disease Testing Becoming Widely Accepted Amongst Clinical Laboratories.
June 19, 2013
DAVIS, Calif. -- Gold Standard Diagnostics, Corp. (GSD, www.gsdx.us), a leading manufacturer and marketer of clinical laboratory instrumentation and assays for the in vitro diagnostics market, announces new Line Immunoassay technology for Lyme confirmation testing. GSD gives clinical laboratories an FDA cleared, improved option for serological confirmation testing for Lyme disease according to the CDC-recommended two-step process. Both the IgG and IgM line blots are substantially equivalent to traditional Western Blot technology, but offer advancements in usability and objectivity through use of Line Immunoassay technology. GSD’s LIA test strips offer numerous enhancements including: improved sensitivity and specificity, consistent results, large lot sizes, easier handling and automation options.
“The demands of today’s clinical laboratories require consistent, reliable and user-friendly products said,” John Griffiths, CEO of Gold Standard Diagnostics. Gold Standard’s innovative quality products, automation options, and excellent service meet those needs. The advanced technology of the GSD Lyme LIA can improve test results, workflow efficiency and cost effectiveness for these clinical laboratories.”